SG48993A1 - Immunopotentiatory agent and physiologically acceptable salts thereof - Google Patents

Immunopotentiatory agent and physiologically acceptable salts thereof

Info

Publication number
SG48993A1
SG48993A1 SG1996004981A SG1996004981A SG48993A1 SG 48993 A1 SG48993 A1 SG 48993A1 SG 1996004981 A SG1996004981 A SG 1996004981A SG 1996004981 A SG1996004981 A SG 1996004981A SG 48993 A1 SG48993 A1 SG 48993A1
Authority
SG
Singapore
Prior art keywords
immunopotentiatory
agent
acceptable salts
physiologically acceptable
combinations
Prior art date
Application number
SG1996004981A
Other languages
English (en)
Inventor
John Richard Rhodes
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220715A external-priority patent/GB9220715D0/en
Priority claimed from GB929226874A external-priority patent/GB9226874D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SG48993A1 publication Critical patent/SG48993A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/11Aldehydes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG1996004981A 1992-10-01 1993-09-17 Immunopotentiatory agent and physiologically acceptable salts thereof SG48993A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220715A GB9220715D0 (en) 1992-10-01 1992-10-01 Immunopotentiatory agent and physiologically acceptable salts thereof
GB929226874A GB9226874D0 (en) 1992-12-23 1992-12-23 Immunopotentiatory agents and physiologically acceptable salts thereof

Publications (1)

Publication Number Publication Date
SG48993A1 true SG48993A1 (en) 1998-05-18

Family

ID=26301715

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004981A SG48993A1 (en) 1992-10-01 1993-09-17 Immunopotentiatory agent and physiologically acceptable salts thereof

Country Status (24)

Country Link
US (1) US5508310A (de)
EP (3) EP0609606B1 (de)
JP (2) JPH07504204A (de)
KR (1) KR100348775B1 (de)
CN (1) CN1213746C (de)
AT (1) ATE146075T1 (de)
AU (1) AU676491B2 (de)
CA (1) CA2124677C (de)
CZ (1) CZ132794A3 (de)
DE (1) DE69306545T2 (de)
DK (1) DK0609606T3 (de)
ES (1) ES2096215T3 (de)
GR (1) GR3022541T3 (de)
HR (1) HRP931243A2 (de)
HU (1) HUT70482A (de)
IL (1) IL107157A0 (de)
MX (1) MX9306079A (de)
NZ (1) NZ256110A (de)
RU (1) RU94028670A (de)
SG (1) SG48993A1 (de)
SI (1) SI9300514A (de)
SK (1) SK65294A3 (de)
WO (1) WO1994007479A2 (de)
YU (1) YU62793A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
KR100578317B1 (ko) * 1997-05-20 2006-05-11 갈레니카 파마슈티칼스 인크. 면역보강성 및 면역자극 활성을 갖는 트리테르펜 사포닌유사체
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
IL135148A0 (en) * 1997-10-03 2001-05-20 Galenica Pharmaceuticals Inc A polysaccharide conjugate and pharmaceutical compositions containing the same
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
ATE308512T1 (de) * 1999-12-21 2005-11-15 Cd45 inhibitoren
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP2003528068A (ja) * 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2001076626A2 (en) * 2000-04-11 2001-10-18 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
WO2002087424A2 (en) * 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US8246969B2 (en) * 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1622554A4 (de) * 2003-05-15 2008-01-02 Bioform Medical Inc Zusammensetzungen mit einer kombination aus einem pharmazeutischen mittel oder einem kosmetischen mittel und einem eine oxy-gruppe tragenden aromatischen aldehyd
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
EP2222328A4 (de) * 2007-11-15 2013-06-05 Endocyte Inc Verfahren zur verabreichung von konjugaten
SG10201602752XA (en) 2011-01-07 2016-05-30 Allergan Inc Melanin modification compositions and methods of use
WO2016144635A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation
MY181892A (en) 2015-07-13 2021-01-12 Beyondspring Pharmaceuticals Inc Plinabulin compositions
SG11201806583XA (en) * 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MY201811A (en) 2017-02-01 2024-03-19 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
JPS5545658A (en) * 1978-09-28 1980-03-31 Rikagaku Kenkyusho Carcinostatic agent
JPS5569510A (en) * 1978-11-16 1980-05-26 Mitsubishi Chem Ind Ltd Carcinostatic agent
EP0054924B1 (de) * 1980-12-18 1986-08-06 The Wellcome Foundation Limited Pharmazeutische Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung
LU85365A1 (de) * 1984-05-16 1986-01-29 Chimicasa Gmbh Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) * 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) * 1985-08-09 1987-02-19 Schleicher Peter Mundpflegemittel
JPS63264409A (ja) * 1988-01-13 1988-11-01 Rikagaku Kenkyusho 制癌剤
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
EP0499015A1 (de) * 1991-02-15 1992-08-19 Fockerman, Jasmine Benzopyranphenolderivate zur Anwendung als bakterienhemmende, antivirale und immunoanregende Mittel

Also Published As

Publication number Publication date
EP0614357A1 (de) 1994-09-14
HUT70482A (en) 1995-10-30
MX9306079A (es) 1994-06-30
WO1994007479A3 (en) 1994-07-21
CN1213746C (zh) 2005-08-10
KR100348775B1 (ko) 2003-02-11
GR3022541T3 (en) 1997-05-31
AU4831193A (en) 1994-04-26
YU62793A (sh) 1998-05-15
RU94028670A (ru) 1996-05-20
DE69306545D1 (de) 1997-01-23
EP0678298A2 (de) 1995-10-25
ES2096215T3 (es) 1997-03-01
WO1994007479A2 (en) 1994-04-14
CA2124677A1 (en) 1994-04-14
CA2124677C (en) 2008-09-09
ATE146075T1 (de) 1996-12-15
SK65294A3 (en) 1995-03-08
IL107157A0 (en) 1993-12-28
HU9401631D0 (en) 1994-08-29
JPH072660A (ja) 1995-01-06
DE69306545T2 (de) 1997-04-03
CZ132794A3 (en) 1995-02-15
JPH07504204A (ja) 1995-05-11
JP3717950B2 (ja) 2005-11-16
EP0609606B1 (de) 1996-12-11
AU676491B2 (en) 1997-03-13
US5508310A (en) 1996-04-16
SI9300514A (en) 1994-06-30
EP0609606A1 (de) 1994-08-10
NZ256110A (en) 1997-07-27
DK0609606T3 (de) 1997-03-17
HRP931243A2 (en) 1995-12-31
CN1091005A (zh) 1994-08-24
EP0678298A3 (de) 1996-05-29

Similar Documents

Publication Publication Date Title
DK0609606T3 (de)
IL96550A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
BR0211228A (pt) Composto, composição farmacêutica e seus usos
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
HK1015137A1 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha d-neuraminic acid
GB9107833D0 (en) Treatment of periodontitis
GB9224598D0 (en) Novel compositions
IL108571A0 (en) Derivatives of quinolonecarboxylic acid and naphthyrdionecarboxylic acid, their preparation and pharmaceutical compositions containing them
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
NO923199L (no) Terapeutiske forbindelser
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
SE8600658D0 (sv) Novel composition of matter
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
HUT50821A (en) Process for producing new ester derivatives of acyclovir and pharmaceutical compositions comprising such compound
TW222622B (de)
GB9126874D0 (en) Medicaments
MX9203900A (es) Composicion farmaceutica que comprende derivados de acido benzimidazolin-2-oxo-1-carboxilico.